We’re delivering science that takes us closer to meaningful change for people with neurological and psychiatric disorders.
In the field of neuroscience, with many tough-to-treat disorders and a high unmet need, our scientists are relentless in their pursuit of raising the standards of care. But the brain is complex, and new challenges require new ways of thinking across all stages of drug discovery and development.
Our work is personal and our pursuit of delivering transformational therapies to help people preserve their personhood is unwavering. That’s why we are continuously exploring innovative, disease-modifying approaches to address some of the most prevalent and serious disorders, from Parkinson’s disease and Alzheimer’s to migraine, schizophrenia and stroke.
We work across all stages of development in search of novel therapeutics and drug-device combinations that have the potential to treat chronic disabling neurological and psychiatric conditions. Our research interests include new disease modification approaches; managing disease symptoms; genetic, molecular and physiological insights.
The burden of neurological and psychiatric disorders can feel insurmountable. But that feeling drives us to take on some of the biggest challenges and unearth potential solutions.
UK-ABBV-260031 | February 2026
You are now leaving the AbbVie UK website. The website you’re visiting is not subject to the AbbVie Privacy Policy, and AbbVie is not responsible for, nor does it endorse content on this third-party site.